Search Within

Brian Kushner

  1. "Pediatrics, Department of"
Formats
  1. Journal Article (181)
  2. Meeting Abstract (113)
  3. Conference Paper (9)
  4. Book Section (4)
  5. Editorial (2)
  6. Guidelines (1)
  7. Review (1)
Groups
  1. Neuroblastoma Service (311)
  2. Pediatrics, Department of (311)
  3. GSK Faculty (233)
  4. Tow Center for Developmental Oncology (TCDO) (233)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (230)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (227)

More Groups

People
  1. Nai-Kong Cheung (227)
  2. Shakeel Modak (154)
  3. Kim Kramer (132)
  4. Michael La Quaglia (80)
  5. Ellen Basu (68)
  6. Stephen Roberts (63)

More People

Years
  1. 2025 (2)
  2. 2024 (9)
  3. 2023 (18)
  4. 2022 (9)
  5. 2021 (13)
  6. 2020 (14)

More Years

Publications
  1. Pediatric Blood and Cancer (65)
  2. Journal of Clinical Oncology (60)
  3. International Journal of Radiation Oncology, Biology, Physics (26)
  4. Cancer (19)
  5. Medical and Pediatric Oncology (10)
  6. Neuro-Oncology (9)

More Publications

Publishers
  1. Wiley Periodicals, Inc (65)
  2. American Society of Clinical Oncology (61)
  3. Elsevier Inc. (33)
  4. Wiley Blackwell (19)
  5. American Association for Cancer Research (14)
  6. Oxford University Press (14)

More Publishers

Results (311)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
    Meeting Abstract

    Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Sørensen, P. S.; Kushner, B.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Plasma cell-free DNA analysis uncovered tumor heterogeneity and clonal evolution during treatment for relapsed neuroblastoma
    Meeting Abstract

    Cardenas, F. I.; Kothari, P.; Tsui, D.; Basu, E.; Roberts, S.; Cheung, N. K.; Kushner, B.; Modak, S.
    Pediatric Blood and Cancer (2022)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Meeting Abstract

    Modak, S.; Pandit Taskar, N.; Kushner, B.; Zanzonico, P.; Humm, J.; Donzelli, M.; Lewis, J.; Lyashchenko, S.; Chu, B.; Larson, S.; more...
    Pediatric Blood and Cancer (2022)

    Fulltext@MSK | Save
  • Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HRNB): Response data and efficacy in patient (pt) subgroups
    Meeting Abstract

    Mora, J.; Chan, G. C. F.; Morgenstern, D. A.; Nysom, K.; Bear, M.; Tornøe, K.; Sørensen, P. S.; Kushner, B. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study
    Meeting Abstract

    Modak, S.; Kushner, B. H.; Mauguen, A.; Castañeda, A.; Varo, A.; Gorostegui, M.; Muñoz, J. P.; Santa-Maria, V.; Basu, E. M.; Cardenas, F. I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Journal Article

    Kramer, K.; Pandit-Taskar, N.; Kushner, B. H.; Zanzonico, P.; Humm, J. L.; Tomlinson, U.; Donzelli, M.; Wolden, S. L.; Haque, S.; Dunkel, I.; more...
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute clinical trials planning meeting
    Guidelines

    Park, J. R.; Villablanca, J. G.; Hero, B.; Kushner, B. H.; Wheatley, K.; Beiske, K. H.; Ladenstein, R. L.; Baruchel, S.; Macy, M. E.; Moreno, L.; more...
    Cancer (2022)

    Fulltext@MSK | Save
  • Bone marrow surveillance of pediatric cancer survivors identifies clones that predict therapy-related leukemia
    Journal Article

    Spitzer, B.; Rutherford, K. D.; Gundem, G.; McGovern, E. M.; Millard, N. E.; Arango Ossa, J. E.; Cheung, I. Y.; Gao, T.; Levine, M. F.; Zhang, Y.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Assessment of corticosteroid premedication for patients treated with the humanized GD2-binding monoclonal antibody naxitamab
    Meeting Abstract

    Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Hindsberger, C.; Kushner, B.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase I trial of oral yeast-derived β-glucan to enhance anti-GD2 immunotherapy of resistant high-risk neuroblastoma
    Journal Article

    Iglesias Cardenas, F.; Mauguen, A.; Cheung, I. Y.; Kramer, K.; Kushner, B. H.; Ragupathi, G.; Cheung, N. K. V.; Modak, S.
    Cancers (2021)

    Fulltext@MSK | Save